WO2003053352A3 - Therapeutic compounds for treating dyslipidemic conditions - Google Patents

Therapeutic compounds for treating dyslipidemic conditions Download PDF

Info

Publication number
WO2003053352A3
WO2003053352A3 PCT/US2002/040236 US0240236W WO03053352A3 WO 2003053352 A3 WO2003053352 A3 WO 2003053352A3 US 0240236 W US0240236 W US 0240236W WO 03053352 A3 WO03053352 A3 WO 03053352A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic compounds
dyslipidemic conditions
treating dyslipidemic
treating
conditions
Prior art date
Application number
PCT/US2002/040236
Other languages
French (fr)
Other versions
WO2003053352A2 (en
Inventor
A Brian Jones
Alan D Adams
Bruno Tse
Shaei Y Huang
Ahren Green
Original Assignee
Merck & Co Inc
A Brian Jones
Alan D Adams
Bruno Tse
Shaei Y Huang
Ahren Green
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, A Brian Jones, Alan D Adams, Bruno Tse, Shaei Y Huang, Ahren Green filed Critical Merck & Co Inc
Priority to EP02795892A priority Critical patent/EP1458694A4/en
Priority to US10/498,771 priority patent/US20040266849A1/en
Priority to CA002470591A priority patent/CA2470591A1/en
Priority to JP2003554112A priority patent/JP2005519042A/en
Priority to AU2002360620A priority patent/AU2002360620A1/en
Publication of WO2003053352A2 publication Critical patent/WO2003053352A2/en
Publication of WO2003053352A3 publication Critical patent/WO2003053352A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Abstract

The present invention relates to novel LXR ligands of Formula (I) and the pharmaceutically acceptable salts and esters thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.
PCT/US2002/040236 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions WO2003053352A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02795892A EP1458694A4 (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions
US10/498,771 US20040266849A1 (en) 2002-12-16 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions
CA002470591A CA2470591A1 (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions
JP2003554112A JP2005519042A (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions
AU2002360620A AU2002360620A1 (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34255601P 2001-12-20 2001-12-20
US60/342,556 2001-12-20

Publications (2)

Publication Number Publication Date
WO2003053352A2 WO2003053352A2 (en) 2003-07-03
WO2003053352A3 true WO2003053352A3 (en) 2003-11-20

Family

ID=23342338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/040236 WO2003053352A2 (en) 2001-12-20 2002-12-16 Therapeutic compounds for treating dyslipidemic conditions

Country Status (5)

Country Link
EP (1) EP1458694A4 (en)
JP (1) JP2005519042A (en)
AU (1) AU2002360620A1 (en)
CA (1) CA2470591A1 (en)
WO (1) WO2003053352A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041704A2 (en) * 1999-12-13 2001-06-14 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
AU2003256655A1 (en) 2002-07-25 2004-02-16 Merck And Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
CA2585623C (en) 2004-10-27 2012-06-05 Daiichi Sankyo Company Limited Ortho-substituted benzene derivatives
ATE455543T1 (en) * 2004-12-14 2010-02-15 Sanofi Aventis Deutschland CYCLOPROPANE ACID DERIVATIVES FOR LOWERING LIPID LEVELS
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN103517908A (en) 2010-09-07 2014-01-15 Seoul大学校产学协力财团 Sesterterpene compounds and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028137A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028137A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] XP002964553, accession no. STN Database accession no. 1997:533628 *
See also references of EP1458694A4 *

Also Published As

Publication number Publication date
WO2003053352A2 (en) 2003-07-03
JP2005519042A (en) 2005-06-30
EP1458694A2 (en) 2004-09-22
EP1458694A4 (en) 2005-12-14
AU2002360620A1 (en) 2003-07-09
CA2470591A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
MY136761A (en) Oxazol derivatives
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
MXPA03011515A (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents.
CA2437844A1 (en) Method for increasing leptin levels using nicotinic acid compounds
EP1633722A4 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
WO2005030120A3 (en) Antiangiogenic agents
WO2005021497A3 (en) Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
GB0130677D0 (en) Medicaments and novel compounds
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
AU2003288231A1 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
WO2002096420A3 (en) Method for treating nerve injury caused by surgery
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
EP1461030A4 (en) Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003051838A3 (en) Protein kinase inhibitors
WO2002096855A3 (en) Anticholinergic compounds and methods of use
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10498771

Country of ref document: US

Ref document number: 2470591

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002795892

Country of ref document: EP

Ref document number: 2003554112

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002360620

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002795892

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002795892

Country of ref document: EP